Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.

Horizontal portrait of Professor Michael Dustin

The National Academy of Sciences (NAS) announced today that Dr Michael L. Dustin is among its 120 newly elected members, recognising distinguished and continuing achievements in original research. Dr Dustin is Professor of Molecular Immunology, and Director of Research at the Kennedy Institute for Rheumatology at NDORMS.  

Professor Fiona Powrie, Director of the Kennedy Institute of Rheumatology, who was also elected to NAS in 2020 said: “Membership of NAS is one of the highest honours a US scientist can receive, and Mike is highly deserving. The award recognises his international leadership in molecular immunology and pioneering work to understand how T lymphocytes recognise and respond to target cells. This has been fundamental for modern day efforts to develop new therapies that target the T cell response, including in immune-oncology. 

“Being elected to NAS is a great honour for me as I was elected by many of my most respected peers from the fields of immunology, cell biology and across the sciences,” said MichaelMy work is highly collaborative, so this is also a recognition of my mentors, including Scott Peterson, Tim Springer, Stuart Kornfeld and Emil Unanue, and all the technicians, students, post-docs, and visiting professors who have spent time in my lab over the past 40 years in science. I'm grateful for all the effort and ingenuity from peers and lab members that my induction into NAS also recognises.” 

On congratulating Michael, Professor Tony Hunter, Molecular and Cell Biology Laboratory, at the Salk Institute, La Jolla, California said: "This is a truly well-deserved recognition of your pioneering work on the reconstitution of the immune synapse on supported lipid bilayers, and what it has taught us."

Michael is the fourth professor from the Kennedy Institute to have been elected to NAS. 

NAS is a private, non-profit institution that was established under a congressional charter signed by President Abraham Lincoln in 1863. It recognises achievement in science by election to membership, and—with the National Academy of Engineering and the National Academy of Medicine—provides science, engineering, and health policy advice to the federal government and other organisations. 

Similar stories

Professor Katja Simon elected to the Academy of Medical Sciences

Awards Kennedy Main

Professor of Immunology Katja Simon has been elected as a Fellow of the Academy of Medical Sciences.

3,400 different medicines used globally to treat COVID-19

Main Statistics and epidemiology

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?